Oruka Therapeutics reported week 28 data from the Phase 2a ORKA-001 psoriasis trial, showing sustained activity with 71.4% achieving PASI 100 and 87.3% attaining PASI 90. The safety profile remains favorable, with no injection-site reactions and only two serious adverse events deemed unrelated. Key upcoming readouts—EVERLAST-A at 52 weeks (Dec 2026) and EVERLAST-B data in Q4 2026—could meaningfully influence ORKA's valuation if durability holds.
Oruka Therapeutics reported strong efficacy for its ORKA-001 treatment, achieving 63.5% complete skin clearance among participants, with favorable safety data. The stock surged 39% as analysts raised price targets, highlighting a competitive edge in psoriasis treatments with a potential for annual dosing.
